Journal of cancer research and therapeutics最新文献

{"title":"Survival prediction using CT-based radiomic features in patients of pancreatic cancer treated with chemotherapy followed by SBRT.","authors":"Divya Khosla, Gaganpreet Singh, Vandana Thakur, Rakesh Kapoor, Rajesh Gupta, Divyesh Kumar, Renu Madan, Shikha Goyal, Arun S Oinam, Surinder S Rana","doi":"10.4103/jcrt.jcrt_1595_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1595_24","url":null,"abstract":"<p><strong>Purpose: </strong>Owing to the heterogeneous nature of pancreatic cancer, clinical prediction models are not sufficient for prognostication. Radiomics is quantitative noninvasive assessment performed from imaging which by means of mathematical models can decode tumor phenotype and further predict disease and treatment outcomes. This pilot study aims to investigate the association of CT-based radiomic features with overall survival (OS) in pancreatic cancer patients treated with stereotactic body radiation therapy (SBRT).</p><p><strong>Materials and methods: </strong>This study was conducted in patients of borderline resectable and locally advanced pancreatic cancer at our institute from January 2021 to December 2022. Ten patients underwent neoadjuvant chemotherapy, followed by SBRT with doses ranging from 33 Gy to 42 Gy administered in 5-6 fractions. Subsequent treatment included additional chemotherapy and evaluation for potential surgery. Radiomic features were extracted from planning CT images, and statistical analysis was performed using R software.</p><p><strong>Results: </strong>Out of 10 patients receiving neoadjuvant chemotherapy followed by SBRT, three underwent surgery. The duration of median follow-up was 15 months, and the median OS was 25 months. A total of 851 radiomic features including 107 original images features and 93 × 8 wavelet-based features were extracted. Using Lasso Cox regression, four wavelet-based features were found to influence the overall survival.</p><p><strong>Conclusions: </strong>The present study demonstrates that CT-based radiomic features can be a promising tool in predicting survival and in addition to clinical parameters can provide detailed prognostic information that can facilitate personalized patient care. However, clinical implications of this radiomic analysis need a larger number of patients to validate the results.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microwave ablation combined with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor treatment in EGFR-mutant advanced non-small cell lung cancer.","authors":"Nana Chen, Xiaojing Tan, Cuiping Han, Feng Zhao, Lu Yang, Dongfeng Wang, Xin Ye, Zhigang Wei","doi":"10.4103/jcrt.jcrt_2418_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2418_24","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to verify the efficacy and safety of microwave ablation (MWA) in combination with third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) administration for EGFR-mutant advanced non-small cell lung cancer (NSCLC).</p><p><strong>Materials and methods: </strong>Individuals with advanced NSCLC and EGFR mutations who underwent third-generation EGFR-TKI treatment and MWA (EGFR-TKI treatment followed by MWA [Group E + M] and MWA followed by EGFR-TKI treatment [Group M + E]) were retrospectively enrolled. The primary endpoint was duration of response (DoR).</p><p><strong>Results: </strong>There were 12 patients in Group E + M and 16 in Group M + E. The overall median DoR was 21.9 months (95% confidence interval [CI]: 17.3-26.4). The median DoR was 25.7 months (95% CI: 20.6-30.9) and 20.5 months (95% CI: 5.9-35.1) in Group E + M and Group M + E (P = 0.996), respectively. When EGFR-TKIs were used as a first-line treatment, the median DoR overall and that of patients in Groups E + M and M + E were 29.3 months (95% CI: 19.2-39.4), 29.3 months (95% CI: 21.0-37.5), and not reached (P = 0.252), respectively. Major complications related to pneumothorax were observed in five patients, with no difference observed between the groups.</p><p><strong>Conclusion: </strong>Patients with advanced EGFR-mutant NSCLC who underwent third-generation EGFR-TKI treatment plus MWA had a superior DoR and experienced minimal complications.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra-arterial chemotherapy for unilateral advanced intraocular retinoblastoma: A long-term review of a case series.","authors":"Yixiao Li, Minglei Han, Dan Song, Jing Li, Zhuang Liu, Xin Zhang, Liang Wang, Lei Guo","doi":"10.4103/jcrt.jcrt_2375_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2375_24","url":null,"abstract":"<p><strong>Background: </strong>The role of intra-arterial chemotherapy (IAC) for globe salvage treatment of retinoblastoma (RB) has been validated clinically; however, data on its long-term effects remain limited. This study examined the long-term stable salvage rate of IAC in treating RB and assessed its potential adverse effects.</p><p><strong>Methods: </strong>Patients diagnosed with unilateral advanced intraocular RB who achieved short-term globe salvage and began IAC treatment at our hospital between December 2016 and September 2019 were selected for this study. The collected clinical data included patient demographics, tumor stage, prior treatment history, course of IAC therapy, complications, combination therapy modalities outside of IAC, and long-term follow-up outcomes.</p><p><strong>Results: </strong>Thirty-nine patients were included with a mean age at initial IAC treatment of 1.84 ± 1.18 years. Tumors were located in the right and left eyes of 22 and 17 patients, respectively. Based on the International Intraocular Retinoblastoma Classification (IIRC) grouping, Group D comprised 61.54%, whereas Group E accounted for 38.46% of the cases. The patients received 122 IAC sessions, with a median of three per patient. Follow-up data revealed a 5-year stable globe salvage rate of 87.18% with no treatment-related complications in 15 cases. The primary long-term adverse effects included cataracts, ocular growth arrest, and choroidal retinal atrophy/optic nerve atrophy.</p><p><strong>Conclusions: </strong>IAC demonstrated excellent long-term therapeutic efficacy and safety for children with unilateral advanced intraocular RB.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"442-446"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supine/prone position fixation treatment in cervical cancer radiotherapy.","authors":"Zhiman Zheng, Dongyue Liu, Yangmei Su","doi":"10.4103/jcrt.jcrt_2050_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2050_24","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to determine the correlation between bladder volume changes and set-up accuracy in cervical cancer patients undergoing radiotherapy.</p><p><strong>Methods: </strong>Forty patients who underwent intensity-modulated radiotherapy were divided into two groups based on their position during treatment: group A (supine) and group B (prone). Correlations between bladder volume changes and set-up accuracy were retrospectively analyzed using archived data and image files.</p><p><strong>Results: </strong>The rate of bladder volume change in group A (-3.99% [-24.51-31.53]) was significantly higher (Z = -2.724; P = 0.006) than that in group B (-14.95% [-41.63-7.64]). The set-up errors in the X (left-right), Y (cranial-caudal), and Z (anterior-posterior) directions were 0.05 ± 2.25 mm, 0.84 ± 2.63 mm, and 0.41 ± 2.35 mm, respectively, in group A and -0.31 ± 2.22 mm, -0.38 ± 2.88 mm, and 0.78 ± 3.41 mm, respectively, in group B. No significant differences in the X and Z directions were detected between the two groups; however, a significant difference was detected in the Y direction. The set-up error in the X direction was positively correlated with the rate of bladder volume change (r = 0.284; P = 0.010) in group A; no correlations were observed in the X, Y, and Z directions in group B.</p><p><strong>Conclusion: </strong>Patients in the prone position demonstrated better performance in the Y direction than those in the supine position. The set-up error in the X direction was positively correlated with the rate of bladder volume change among patients in the supine position.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"401-408"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomics analysis explored the changes in the tumor microenvironment of CT26 tumor-bearing mice after microwave ablation.","authors":"Huiwen Xue, Zhen Li, Lu Yu, Qianqian Lu, Siyi Niu, Jing Liang, Zhigang Wei, Xin Ye, Qi Xie","doi":"10.4103/jcrt.jcrt_2113_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2113_24","url":null,"abstract":"<p><strong>Background: </strong>Microwave ablation (MWA) effectively generates large high-temperature ablation zones. This modality achieves direct tumor destruction while stimulating antitumor immunity and potentially inducing abscopal effects, though with limited systemic efficacy. Emerging evidence suggests post-MWA tumor microenvironment (TME) modifications critically influence immune activation, yet the underlying mechanisms remain poorly understood. Notably, localized proteomic changes in the TME following MWA require comprehensive characterization to elucidate its immunomodulatory properties.</p><p><strong>Aim of the study: </strong>This study investigates proteomic changes in TME after MWA to identify critical protein signatures modulating antitumor immunity.</p><p><strong>Material and methods: </strong>This study utilized a Balb/c murine model with subcutaneous CT26 cell injections to assess MWA effects on the TME. MWA treatment (5 w-3 min) was administered using a microwave generator, followed by LC-MS analysis using a tims TOF Pro with gradient elution and parallel accumulation serial fragmentation data collection. Protein expression differences were analyzed via t-test and further interpreted with Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway bioinformatics.</p><p><strong>Results: </strong>MWA induced substantial proteomic changes, with 545 upregulated and 678 downregulated proteins compared to controls. Integrated bioinformatics analysis demonstrated significant alterations in biological processes, cellular components, and molecular functions, particularly enriched in tumor cell growth-related pathways. Protein interaction network analysis identified pivotal hub proteins such as cap-binding protein subunit 1 (NCBP1) and cell division cycle 5-like protein (CDC5L) potentially mediating cellular responses to MWA treatment.</p><p><strong>Conclusion: </strong>MWA significantly induced protein alterations in TME, with NCBP1 and CDC5L standing out as promising candidate targets for tumor treatment.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"494-503"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of epirubicin and cyclophosphamide for the treatment of advanced pulmonary sarcomatoid carcinoma: A case report and literature review.","authors":"Ruoyu Deng, Jialing Lv, Fang Wang, Yanqiong Chen, Junfeng Wang, Lin Wang, Lixia Mu, Zhijun Zhang, Wen Zhang, Chao Zhang","doi":"10.4103/jcrt.jcrt_361_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_361_24","url":null,"abstract":"<p><strong>Abstract: </strong>Pulmonary sarcomatoid carcinoma (PSC) is a rare and atypical subset of non-small-cell lung cancer (NSCLC) characterized by its aggressive nature, poor prognosis, and limited responsiveness to conventional therapeutic modalities. The effectiveness of chemotherapy in managing PSC remains controversial, with platinum-based regimens often yielding unsatisfactory outcomes in advanced PSC patients. Herein, we present a male patient with PSC who did not have a driver gene mutation or express the programmed death ligand 1. He received combination chemotherapy of epirubicin and cyclophosphamide for the first time, which resulted in progression-free survival for seven months and a noteworthy partial tumor response. These findings suggest that the combination of epirubicin and cyclophosphamide might prove promising as a therapeutic option for patients diagnosed with PSC. Nevertheless, the significance of this novel approach necessitates further validation through high-quality clinical trials.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"512-517"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MSNs-loaded HMME and Erastin-mediated ferroptosis combined with sonodynamic therapy for HCC treatment.","authors":"Chang Zhao, Guchun Qin, Caixia Ling, Yang Zhao, Yunxi Huang, Zelong Jiang, Niqiang Zhou, Junjie Liu, Danke Su, Jinghang Jiang","doi":"10.4103/jcrt.jcrt_1531_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1531_24","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis can have a major impact on the development and advancement of hepatocellular carcinoma (HCC) due to its clear association with heightened vulnerability to the disease. This study aimed to develop a novel nanoplatform to evaluate its effectiveness in in vivo and in vitro models of HCC.</p><p><strong>Methods: </strong>Erastin, a compound that induces iron-dependent cell death, and HMME, a sonosensitizer, were enclosed within mesoporous silica nanoparticles (MSNs). The nanoparticles were engineered to exhibit a responsive assembly-disassembly mechanism. Hydrophilic hyaluronic acid (HA) was utilized for conjugation modification to synthesize Erastin/HMME@MSNs-HA. In vivo and in vitro experiments were conducted to elucidate the antitumor mechanisms of this nanomaterial.</p><p><strong>Results: </strong>In the in vitro cellular experiments, Erastin/HMME@MSNs-HA was rapidly degraded by hyaluronidase, leading to increased endocytosis of the cancer cells. Cellular breakdown led to the generation of harmful reactive oxygen species (ROS), decreased glutathione levels, and increased lipid peroxidation, resulting in a decrease in mitochondrial membrane potential, dysfunctional mitochondria, reduced cell growth, and increased cell death. Additionally, the Erastin/HMME@MSNs-HA nanotherapy platform, when combined with ultrasound (US) treatment, exhibited significant therapeutic effectiveness against tumors in vivo. It induced significant cell death in cancerous tissues, decreased tumor growth, worsened tissue oxygen deprivation, and exhibited good compatibility with the body.</p><p><strong>Conclusion: </strong>These findings indicate that the nanoplatform can effectively alleviate tumor hypoxia while inducing apoptosis and ferroptosis, laying the foundation for enhancing the efficacy of ROS-mediated HCC therapy.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"465-476"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acoustically activated nanoplatforms achieve tumor regression by exacerbating tumor hypoxia.","authors":"Caixia Ling, Shanshan Ma, Mengqi Zhang, Danke Su, Zixuan Liang","doi":"10.4103/jcrt.jcrt_1838_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1838_24","url":null,"abstract":"<p><strong>Background: </strong>Rapid tumor proliferation can be mitigated by \"starving the cancer cells\" through nutrient and oxygen blood supply blockade to the tumor, which is a significant challenge in oncological treatment.</p><p><strong>Methods: </strong>We developed a multipathway nano platform designed to improve hypoxia-exacerbated cancer starvation therapy. This was achieved by co-loading the acoustic sensitizer-IR780-and the vascular disruptor-vadimezan (DMXAA)-into dendritic silica nanocarriers to establish acid-responsive nanoplatforms, termed DMXAA/IR780@SiO2 (DIS NPs), using a simple one-pot synthesis method. In vivo and in vitro experiments were conducted to determine the antitumor mechanisms of this nanomaterial.</p><p><strong>Results: </strong>In vitro cellular experiments revealed that reaching the acidic tumor microenvironment value with DMXAA/IR780@SiO2 degrades silica in DIS NPs, accompanied by the release of the drug, and the released DMXAA damaged blood vessels at the tumor site, thereby blocking oxygen and nutrient supplies. Concurrently, the acoustic sensitizer-IR780-released after the cleavage of DIS NPs generates reactive oxygen species under the action of ultrasound (US), thereby depleting oxygen, further aggravating tumor hypoxia, and damaging the mitochondria by disrupting the redox reaction, which ultimately triggers cellular damage and even death. Further, a significant therapeutic effect on tumors in vivo was observed when combined with ultrasound US therapy, demonstrating synergistic therapeutic effects in terms of acoustic dynamics and vascular disruption, as well as good biosafety.</p><p><strong>Conclusion: </strong>The DIS NPs exhibit a promising approach for hypoxia-exacerbated cancer starvation therapy, providing a potential new avenue for cancer treatment with demonstrated efficacy and biocompatibility.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"371-380"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upfront autologous hematopoietic stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma: A real-world multicenter study.","authors":"Zhi Guo, Xiaomin Xian, Xiaochen Xiang, Jun Wang, Zhiqiang Sun, Yueqiao Wang, Jing Xie, Jingye Meng, Yongqian Li, Min Zhou, Guowei Li, Bo Lu, Xiaojun Xu, Liang Wang, Qiang Wang","doi":"10.4103/jcrt.jcrt_2102_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2102_24","url":null,"abstract":"<p><strong>Background and purpose: </strong>The ability of autologous hematopoietic stem cell transplantation (ASCT) to improve the benefit of patients with high-risk diffuse large B-cell lymphoma (DLBCL) who achieved complete remission (CR) following induction chemotherapy is controversial. This multicenter real-world study aimed to explore the efficacy and safety of the rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen followed by consolidated ASCT therapy in newly diagnosed DLBCL.</p><p><strong>Methods: </strong>From June 2018 to June 2021, the clinical data of patients with high-risk DLBCL who reached CR after receiving the R-CHOP regimen from ten lymphoma diagnosis and treatment centers were analyzed. Patients were included in the R-CHOP+ASCT (with consolidated ASCT therapy, n = 60) and R-CHOP (follow-up without consolidated ASCT therapy, n = 60) groups. The efficacy in the two groups was compared by difference analysis, and the safety of R-CHOP+ASCT was analyzed.</p><p><strong>Results: </strong>Until June 2024, the median follow-up times for the R-CHOP+ASCT and R-CHOP groups were 44 (37.25-56) and 43.5 (38-52) months, respectively. Survivors were followed up for at least 36 months. In the R-CHOP+ASCT group, the 3-year disease-free survival (DFS) and overall survival (OS) rates were 89.7% and 96.7% and those in the R-CHOP group were 63.9% and 85.9%, respectively. The 3-year DFS rate in the R-CHOP+ASCT group was significantly higher than that in the R-CHOP group (89.7% vs 63.9%, P = 0.001); no significant difference was found in the 3-year OS rate between the R-CHOP+ASCT and R-CHOP groups (96.7% vs 85.9%, P = 0.113). The 5-year DFS and OS rates in the R-CHOP+ASCT group were 73.6% and 77.6% and those in the R-CHOP group were 56.5% and 81.1%, respectively. The 5-year DFS rate in the R-CHOP+ASCT group was significantly higher than that in the R-CHOP group (73.6% vs 56.5%, P = 0.009), whereas no significant difference was found in the 5-year OS rate between the R-CHOP+ASCT and R-CHOP groups (77.6% vs 81.1%, P = 0.246). In the Cox multifactorial analysis, discontinuous consolidated ASCT therapy, bone marrow invasion, and dual expression were poor prognostic factors that affect DFS [hazard ratio (HR), 5.710; 95% confidence interval (CI), 2.241-14.548, P < 0.001; HR, 4.324; 95% CI, 1.890-9.893, P = 0.001; HR, 2.565; 95% CI, 1.145-5.747, P = 0.022, respectively] and dual expression was a poor prognostic factor for OS (HR, 3.486; 95% CI, 1.300-9.344, P = 0.013). Grade IV myelosuppression after transplantation developed in the R-CHOP+ASCT group, and other common grade 3 or 4 treatment-related adverse events were infection and fever.</p><p><strong>Conclusion: </strong>For patients with newly diagnosed high-risk DLBCL, consolidated ASCT therapy can increase the DFS rate of those with CR status following the R-CHOP regimen, and the safety is controllable.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"447-456"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An analysis of the clinical efficacy and safety of a temperature-sensitive liquid embolic agent loaded with lobaplatin for the treatment of unresectable primary hepatocellular carcinoma through chemoembolization.","authors":"Shengyu Zhou, Qingfeng Lin, Junsheng Zhong, Jian Chen","doi":"10.4103/jcrt.jcrt_2250_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2250_24","url":null,"abstract":"<p><strong>Objective: </strong>To explore the clinical value of transcatheter arterial chemoembolization (TACE) using a temperature-sensitive liquid embolic agent for the interventional treatment of primary hepatocellular carcinoma.</p><p><strong>Methods: </strong>The clinical data and follow-up results sourced from the First Affiliated Hospital of Fujian Medical University were retrospectively analyzed from February 2023 to May 2023. Clinical efficacy was assessed through follow-up imaging using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. In addition, adverse reactions and adverse events were observed and classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTC) version 3.0.</p><p><strong>Results: </strong>Among the 11 patients analyzed in this study, a total of 41 lesions were identified. The average maximum diameter of the lesions was 3.55 ± 1.88 cm (range: 1.70 cm-6.60 cm). One month postoperatively, the efficacy assessment revealed complete response (CR) in 1 case, partial response (PR) in 9 cases, stable disease (SD) in 1 case, and progression in 0 case. The objective response rate (CR + PR) was 90.91%, and the disease control rate (CR + PR + SD) was 100%. Postoperative adverse reactions were mostly of grade 1-2, including abdominal pain, bloating, fever, nausea, and vomiting.</p><p><strong>Conclusion: </strong>The use of temperature-sensitive liquid embolic agents loaded with lobaplatin for chemoembolization in the treatment of unresectable primary liver cancer is a safe and effective therapeutic modality.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"504-508"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}